UA42875U - Method for inducing ovulation in hyperadrogenous infertility - Google Patents

Method for inducing ovulation in hyperadrogenous infertility

Info

Publication number
UA42875U
UA42875U UAU200901684U UAU200901684U UA42875U UA 42875 U UA42875 U UA 42875U UA U200901684 U UAU200901684 U UA U200901684U UA U200901684 U UAU200901684 U UA U200901684U UA 42875 U UA42875 U UA 42875U
Authority
UA
Ukraine
Prior art keywords
hyperadrogenous
infertility
inducing ovulation
days
drug
Prior art date
Application number
UAU200901684U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Александр Григорьевич Резников
Елена Николаевна Борис
Надежда Дмитриевна Носенко
Петр Васильевич Синицын
Любовь Ивановна Полякова
Лариса Васильевна Тарасенко
Original Assignee
Государственное Учреждение "Институт Эндокринологии И Обмена Веществ Им. В.П. Комиссаренко Академии Медицинских Наук Украины"
Александр Григорьевич Резников
Елена Николаевна Борис
Надежда Дмитриевна Носенко
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное Учреждение "Институт Эндокринологии И Обмена Веществ Им. В.П. Комиссаренко Академии Медицинских Наук Украины", Александр Григорьевич Резников, Елена Николаевна Борис, Надежда Дмитриевна Носенко filed Critical Государственное Учреждение "Институт Эндокринологии И Обмена Веществ Им. В.П. Комиссаренко Академии Медицинских Наук Украины"
Priority to UAU200901684U priority Critical patent/UA42875U/en
Publication of UA42875U publication Critical patent/UA42875U/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The method for inducing ovulation in hyperadrogenous infertility comprises the use of non-steroid antiandrogenous drug Flutamide. The drug is taken per os for 8-10 days followed by intramuscular administration at the minimally effective doses. For three days, follicle-stimulating hormone is administered, and two days later the single dose of luteinizing hormone is used.
UAU200901684U 2009-02-26 2009-02-26 Method for inducing ovulation in hyperadrogenous infertility UA42875U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU200901684U UA42875U (en) 2009-02-26 2009-02-26 Method for inducing ovulation in hyperadrogenous infertility

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU200901684U UA42875U (en) 2009-02-26 2009-02-26 Method for inducing ovulation in hyperadrogenous infertility

Publications (1)

Publication Number Publication Date
UA42875U true UA42875U (en) 2009-07-27

Family

ID=50633178

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU200901684U UA42875U (en) 2009-02-26 2009-02-26 Method for inducing ovulation in hyperadrogenous infertility

Country Status (1)

Country Link
UA (1) UA42875U (en)

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
AR092177A1 (en) METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
UA115139C2 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MX2021008247A (en) Combination of dextromethorphan and bupropion for treating depression.
MX2019012884A (en) Combination therapy.
CL2016001411A1 (en) Solid pharmaceutical dosage unit of oral disintegration comprising an estetrol component; Preparation method; use for female contraception and in female hormone replacement therapy.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
NZ595767A (en) Composition for the treatment of prostate cancer
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
RU2017120184A (en) DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE
RU2020120156A (en) TREATMENT AND LOSS OF BONE TISSUE CAUSED BY ANDROGENIC DEPRIVATION THERAPY USING CIS-CLOMIFEN
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
MX2020000164A (en) Isotretinoin oral-mucosal formulations and methods for using same.
UA115250C2 (en) Pharmaceutical combinations
MX2023002649A (en) New formulation of gamma-aminobutyric acid.
UA42875U (en) Method for inducing ovulation in hyperadrogenous infertility
AR097613A1 (en) DOSAGE OF GIP / GLP-1 CO-ANTAGONIST PEPTIDES FOR HUMAN ADMINISTRATION
MX2018005298A (en) Dosage regimen for a phosphatidylinositol 3-kinase inhibitor.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
AR061046A1 (en) MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN
MX2015016678A (en) Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid.
JOP20170044B1 (en) Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency